Industry News (Blood Substitutes)

Commencement Of Oxygent Studies Announced

Published in Blood Weekly, November 6th, 1995

Alliance Pharmaceutical Corp. (Alliance), San Diego, California, announced that a Phase IIb clinical (human) study with Oxygent, a temporary "blood substitute," has commenced.

Oxygent (perflubron emulsion) is intended to reduce or eliminate the need for allogeneic (donor) blood during surgery. The current study is a randomized, controlled, efficacy trial involving surgical patients at multiple sites in the U.S. A similar study is expected to start in Europe shortly. Oxygent is being co-developed by Alliance and Ortho Biotech Inc. and The R.W. Johnson Pharmaceutical Research Institute, members of the Johnson & Johnson Family of Companies.

Alliance...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry